These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

665 related items for PubMed ID: 19846031

  • 1. Ustekinumab for the treatment of moderate to severe psoriasis.
    Gospodarevskaya E, Picot J, Cooper K, Loveman E, Takeda A.
    Health Technol Assess; 2009 Oct; 13 Suppl 3():61-6. PubMed ID: 19846031
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Adalimumab for the treatment of psoriasis.
    Turner D, Picot J, Cooper K, Loveman E.
    Health Technol Assess; 2009 Sep; 13 Suppl 2():49-54. PubMed ID: 19804689
    [Abstract] [Full Text] [Related]

  • 4. Entecavir for the treatment of chronic hepatitis B infection.
    Shepherd J, Gospodarevskaya E, Frampton G, Cooper K.
    Health Technol Assess; 2009 Oct; 13 Suppl 3():31-6. PubMed ID: 19846026
    [Abstract] [Full Text] [Related]

  • 5. Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Ramaekers BLT, Wolff RF, Pouwels X, Oosterhoff M, Van Giessen A, Worthy G, Noake C, Armstrong N, Kleijnen J, Joore MA.
    Pharmacoeconomics; 2018 Aug; 36(8):917-927. PubMed ID: 29480455
    [Abstract] [Full Text] [Related]

  • 6. Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.
    Wade R, Grosso A, South E, Rothery C, Saramago P, Schmitt L, Wright K, Palmer S.
    Pharmacoeconomics; 2019 Feb; 37(2):131-139. PubMed ID: 30112635
    [Abstract] [Full Text] [Related]

  • 7. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
    Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Vergel YB, Misso K, Light K, Chalmers R, Sculpher M, Riemsma R.
    Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
    [Abstract] [Full Text] [Related]

  • 8. Telbivudine for the treatment of chronic hepatitis B infection.
    Hartwell D, Jones J, Harris P, Cooper K.
    Health Technol Assess; 2009 Oct; 13 Suppl 3():23-30. PubMed ID: 19846025
    [Abstract] [Full Text] [Related]

  • 9. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.
    Ward S, Pilgrim H, Hind D.
    Health Technol Assess; 2009 Jun; 13 Suppl 1():1-6. PubMed ID: 19567207
    [Abstract] [Full Text] [Related]

  • 10. Omalizumab for the treatment of severe persistent allergic asthma.
    Jones J, Shepherd J, Hartwell D, Harris P, Cooper K, Takeda A, Davidson P.
    Health Technol Assess; 2009 Sep; 13 Suppl 2():31-9. PubMed ID: 19804687
    [Abstract] [Full Text] [Related]

  • 11. Rituximab for the treatment of rheumatoid arthritis.
    Bagust A, Boland A, Hockenhull J, Fleeman N, Greenhalgh J, Dundar Y, Proudlove C, Kennedy T, Moots R, Williamson P, Dickson R.
    Health Technol Assess; 2009 Sep; 13 Suppl 2():23-9. PubMed ID: 19804686
    [Abstract] [Full Text] [Related]

  • 12. Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Greenhalgh J, Bagust A, Boland A, Fleeman N, McLeod C, Dundar Y, Proudlove C, Shaw R.
    Health Technol Assess; 2009 Oct; 13 Suppl 3():49-54. PubMed ID: 19846029
    [Abstract] [Full Text] [Related]

  • 13. Golimumab for the treatment of psoriatic arthritis.
    Yang H, Epstein D, Bojke L, Craig D, Light K, Bruce I, Sculpher M, Woolacott N.
    Health Technol Assess; 2011 May; 15 Suppl 1():87-95. PubMed ID: 21609657
    [Abstract] [Full Text] [Related]

  • 14. Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal.
    Stevenson M, Pandor A.
    Health Technol Assess; 2009 Oct; 13 Suppl 3():37-42. PubMed ID: 19846027
    [Abstract] [Full Text] [Related]

  • 15. Certolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis.
    Connock M, Tubeuf S, Malottki K, Uthman A, Round J, Bayliss S, Meads C, Moore D.
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):1-10. PubMed ID: 21047485
    [Abstract] [Full Text] [Related]

  • 16. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
    Stevenson M, Scope A, Holmes M, Rees A, Kaltenthaler E.
    Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
    [Abstract] [Full Text] [Related]

  • 17. Cost utility analysis based on a head-to-head Phase 3 trial comparing ustekinumab and etanercept in patients with moderate-to-severe plaque psoriasis: a Canadian perspective.
    Pan F, Brazier NC, Shear NH, Jivraj F, Schenkel B, Brown R.
    Value Health; 2011 Oct; 14(5):652-6. PubMed ID: 21839402
    [Abstract] [Full Text] [Related]

  • 18. Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis.
    Ferrándiz C, García A, Blasco AJ, Lázaro P.
    J Eur Acad Dermatol Venereol; 2012 Jun; 26(6):768-77. PubMed ID: 22126264
    [Abstract] [Full Text] [Related]

  • 19. The Clinical and Cost Effectiveness of Ustekinumab for the Treatment of Psoriatic Arthritis: A Critique of the Evidence.
    O'Connor J, Rice S, Smith A, Rodgers M, Lopez RR, Craig D, Woolacott N.
    Pharmacoeconomics; 2016 Apr; 34(4):337-48. PubMed ID: 26818809
    [Abstract] [Full Text] [Related]

  • 20. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal.
    Holmes M, Carroll C, Papaioannou D.
    Health Technol Assess; 2009 Sep; 13 Suppl 2():55-62. PubMed ID: 19804690
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.